Ágh Tamás, Garuolienė Kristina, Granas Anne Gerd, Gregório João, Aksoy Nilay, Khanyk Nataliia, Ortner Hadžiabdić Maja, Kardas Przemyslaw
Syreon Research Institute, Budapest, Hungary.
Pharmacy Center, Institute of Biomedical Science, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Front Pharmacol. 2024 Oct 4;15:1390629. doi: 10.3389/fphar.2024.1390629. eCollection 2024.
This study tackles the critical challenge of medication non-adherence in healthcare by pinpointing indicators related to medication adherence (IRMAs) across 39 European countries and Israel. Utilizing a structured expert survey methodology within the European Network to Advance Best Practices and Technology on Medication Adherence (ENABLE; COST Action CA19132), our research identified key country-specific IRMAs and collected data on these indicators to understand the multifaceted nature of medication adherence. The research was conducted in two phases: firstly, defining key IRMAs through a two-round expert survey, and secondly, gathering country-specific data on these IRMAs through literature reviews and additional expert surveys. The study revealed a diverse range of 26 top-ranked IRMAs, including six related to country characteristics, four to social/economic factors, three each to therapy-related and patient-related factors, one to condition-related factors, and nine to healthcare system-related factors. The availability of country-specific data on these IRMAs varied among the countries, highlighting the need for more comprehensive data collection and research. The findings from this study not only underscore the complexity of predicting medication adherence but also lay the groundwork for developing targeted, country-specific interventions to improve adherence. Moreover, this research offers valuable insights for policymakers, highlighting the importance of understanding the multifaceted nature of medication adherence and offering a valuable resource in formulating targeted health policies to enhance health outcomes and reduce the economic burden associated with medication non-adherence.
本研究通过确定39个欧洲国家和以色列与药物依从性相关的指标(IRMAs),应对了医疗保健中药物不依从这一关键挑战。我们在欧洲推进药物依从性最佳实践和技术网络(ENABLE;成本行动CA19132)内采用结构化专家调查方法,确定了特定国家的关键IRMAs,并收集了这些指标的数据,以了解药物依从性的多面性。该研究分两个阶段进行:首先,通过两轮专家调查确定关键IRMAs;其次,通过文献综述和额外的专家调查收集这些IRMAs的特定国家数据。研究揭示了26个排名靠前的IRMAs,包括6个与国家特征相关的指标、4个与社会/经济因素相关的指标、3个与治疗相关和患者相关因素的指标、1个与病情相关因素的指标以及9个与医疗保健系统相关因素的指标。各国关于这些IRMAs的特定国家数据可用性各不相同,这凸显了更全面数据收集和研究的必要性。这项研究的结果不仅强调了预测药物依从性的复杂性,还为制定有针对性的、特定国家的干预措施以提高依从性奠定了基础。此外,这项研究为政策制定者提供了宝贵的见解,强调了理解药物依从性多面性的重要性,并为制定有针对性的卫生政策提供了宝贵资源,以改善健康结果并减轻与药物不依从相关的经济负担。